Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care
PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, the leader in...
ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care
Showcasing the future of ophthalmic research at ARVO 2025: ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying research...
Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime1 Previous studies have shown that VETMEDIN® could help improve the survival time and quality of life for dogs with congestive...
